Salud financiera de hoja de balance de ACADIA Pharmaceuticals
Salud financiera controles de criterios 6/6
ACADIA Pharmaceuticals tiene un patrimonio de accionistas total de $577.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $976.9M y $399.7M respectivamente. El BAIT de ACADIA Pharmaceuticals es de $112.2M, por lo que su ratio de cobertura de intereses es de -4.8. Tiene efectivo e inversiones a corto plazo que ascienden a $565.3M.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | -4.8x |
| Efectivo | US$565.33m |
| Patrimonio | US$577.18m |
| Total pasivo | US$399.69m |
| Activos totales | US$976.87m |
Actualizaciones recientes sobre salud financiera
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Recent updates
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($788.3M) de ACAD superan a sus pasivos a corto plazo ($343.9M).
Pasivo a largo plazo: Los activos a corto plazo de ACAD ($788.3M) superan a sus pasivos a largo plazo ($55.7M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ACAD está libre de deudas.
Reducción de la deuda: ACAD no ha tenido ninguna deuda en los últimos 5 años.
Cobertura de la deuda: ACAD no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.
Cobertura de intereses: ACAD no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.